Literature DB >> 24385384

The mannose-sensitive hemagglutination pilus strain of Pseudomonas aeruginosa shift peritoneal milky spot macrophages towards an M1 phenotype to dampen peritoneal dissemination.

Zhi-Feng Miao1, Ting-Ting Zhao, Feng Miao, Zhen-Ning Wang, Ying-Ying Xu, Xiao-Yun Mao, Jian Gao, Jian-Hua Wu, Xing-Yu Liu, Yi You, Hao Xu, Hui-Mian Xu.   

Abstract

Peritoneal dissemination (PD) of tumor cells is the most frequent pattern of gastric cancer recurrence and the leading cause of death. Peritoneal milky spots are deemed as the site of origin of gastric cancer PD wherein the main cellular components are macrophages. A vaccine derived from the mannose-sensitive hemagglutination pilus strain of Pseudomonas aeruginosa (PA-MSHA) has exhibit strong immune modulatory properties. In the present study, we tested the hypothesis whether the PA-MSHA vaccine activated peritoneal milky spot macrophages (PMSM) in a manner that would attenuate PD. It was observed that PA-MSHA activated PMSM towards a classical activation phenotype via a toll-like receptor4/9-dependent mechanism, which increased interleukin-12 levels and promoted the expression of co-stimulatory and antigen-presenting molecules like CD80, CD86, and MHC-II (P < 0.05). In addition, PA-MSHA-treated PMSM exhibited strong nonspecific antitumor effects in both contact-dependent and contact-independent modes of action (P < 0.05). In mice treated with PA-MSHA before inoculating gastric cancer cells, we noted alleviated PD toward the untreated mice. In conclusion, our findings demonstrated that PA-MSHA can stimulate PMSM towards an M1 phenotype and that activated PMSM inhibit gastric cancer growth and PD both in vitro and in vivo. The results of the current study provide a mechanistic insight that is relevant to the potential application of PA-MSHA in the treatment of gastric cancer-mediated PD.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24385384     DOI: 10.1007/s13277-013-1559-4

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  32 in total

Review 1.  Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm.

Authors:  Subhra K Biswas; Alberto Mantovani
Journal:  Nat Immunol       Date:  2010-09-20       Impact factor: 25.606

2.  Neoadjuvant treatment of regional stage IIIB melanoma with high-dose interferon alfa-2b induces objective tumor regression in association with modulation of tumor infiltrating host cellular immune responses.

Authors:  Stergios J Moschos; Howard D Edington; Stephanie R Land; Uma N Rao; Drazen Jukic; Janice Shipe-Spotloe; John M Kirkwood
Journal:  J Clin Oncol       Date:  2006-07-01       Impact factor: 44.544

3.  Insufficient ability of omental milky spots to prevent peritoneal tumor outgrowth supports omentectomy in minimal residual disease.

Authors:  S J Oosterling; G J van der Bij; M Bögels; J R M van der Sijp; R H J Beelen; S Meijer; M van Egmond
Journal:  Cancer Immunol Immunother       Date:  2005-11-26       Impact factor: 6.968

4.  Omental milky spots in screening gastric cancer stem cells.

Authors:  L Cao; X Hu; Y Zhang; X T Sun
Journal:  Neoplasma       Date:  2011       Impact factor: 2.575

Review 5.  Gastric cancer.

Authors:  Vincenzo Catalano; Roberto Labianca; Giordano D Beretta; Gemma Gatta; Filippo de Braud; Eric Van Cutsem
Journal:  Crit Rev Oncol Hematol       Date:  2009-02-20       Impact factor: 6.312

Review 6.  Tregs and rethinking cancer immunotherapy.

Authors:  Tyler J Curiel
Journal:  J Clin Invest       Date:  2007-05       Impact factor: 14.808

7.  Recombinant bacillus Calmette-Guérin (BCG) expressing interferon-alpha 2B enhances human mononuclear cell cytotoxicity against bladder cancer cell lines in vitro.

Authors:  Wujiang Liu; Michael A O'Donnell; Xiaohong Chen; Ruifa Han; Yi Luo
Journal:  Cancer Immunol Immunother       Date:  2009-02-13       Impact factor: 6.968

8.  Milky spots in the greater omentum are predominant sites of local tumour cell proliferation and accumulation in the peritoneal cavity.

Authors:  L F Krist; M Kerremans; D M Broekhuis-Fluitsma; I L Eestermans; S Meyer; R H Beelen
Journal:  Cancer Immunol Immunother       Date:  1998-12       Impact factor: 6.968

9.  NK1.1+ cells mediate the antitumor effects of a dual Toll-like receptor 7/8 agonist in the disseminated B16-F10 melanoma model.

Authors:  Calin D Dumitru; Mary A Antonysamy; Kevin S Gorski; Dave D Johnson; Laxma G Reddy; Jody L Lutterman; Melissa M Piri; Joel Proksch; Sean M McGurran; Elaine A Egging; Felicia R Cochran; Kenneth E Lipson; Mark A Tomai; Gary W Gullikson
Journal:  Cancer Immunol Immunother       Date:  2008-09-13       Impact factor: 6.968

10.  The MSHA strain of Pseudomonas aeruginosa activated TLR pathway and enhanced HIV-1 DNA vaccine immunoreactivity.

Authors:  Jue Hou; Yong Liu; Ying Liu; Yiming Shao
Journal:  PLoS One       Date:  2012-10-15       Impact factor: 3.240

View more
  1 in total

Review 1.  Pseudomonas aeruginosa in Cancer Therapy: Current Knowledge, Challenges and Future Perspectives.

Authors:  Zheng Pang; Meng-Di Gu; Tong Tang
Journal:  Front Oncol       Date:  2022-04-28       Impact factor: 5.738

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.